Physician profile
Daniel Correa
NPI 1437745205
$3,441.14
in general payments reported to CMS, 2019-2025
26 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $14.51 · 2023: $46.21 · 2024: $1,499 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $655.72 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $434.25 | 2021-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $385.11 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $347.42 | 2024-2025 | |
| Lilly USA, LLC | $328.78 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.40 | 2024-2025 | Jardiance |
| Stryker Corporation | $137.04 | 2024 | Insignia |
| Abbvie INC. | $113.50 | 2024-2025 | |
| Vyne Pharmaceuticals INC. | $111.35 | 2021 | |
| Exact Sciences Corporation | $106.53 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.80 | 2024-2025 | Xifaxan |
| Amgen INC. | $57.46 | 2025 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $50.79 | 2024 | Rexulti |
| Seqirus USA INC | $48.23 | 2024-2025 | Fluad, Flucelvax |
| Astellas Pharma US INC | $39.61 | 2024-2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.52 | 2025 | Dexcom G6 Transmitter |
| Phadia US INC. | $32.29 | 2021-2022 | |
| Corcept Therapeutics | $31.47 | 2025 | Korlym |
| Shield Therapeutics INC | $27.43 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.16 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.56 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $21.41 | 2025 | Capvaxive |
| Boston Scientific Corporation | $21.11 | 2025 | Watchman Flx |
| Mylan Specialty L.P. | $20.64 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $17.91 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $14.65 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.